AU2023281591A1 - Treatment method using mazdutide - Google Patents

Treatment method using mazdutide Download PDF

Info

Publication number
AU2023281591A1
AU2023281591A1 AU2023281591A AU2023281591A AU2023281591A1 AU 2023281591 A1 AU2023281591 A1 AU 2023281591A1 AU 2023281591 A AU2023281591 A AU 2023281591A AU 2023281591 A AU2023281591 A AU 2023281591A AU 2023281591 A1 AU2023281591 A1 AU 2023281591A1
Authority
AU
Australia
Prior art keywords
weeks
target compound
administering
patient
weekly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023281591A
Other languages
English (en)
Inventor
Chenghang CAI
Huan DENG
Meng Liu
Baili SONG
Jie Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics (Suzhou) Co Ltd
Original Assignee
Innovent Biologics (Suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics (Suzhou) Co Ltd filed Critical Innovent Biologics (Suzhou) Co Ltd
Publication of AU2023281591A1 publication Critical patent/AU2023281591A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
AU2023281591A 2022-06-01 2023-05-10 Treatment method using mazdutide Pending AU2023281591A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210622648.7 2022-06-01
CN202210622648 2022-06-01
PCT/CN2023/093311 WO2023231730A2 (zh) 2022-06-01 2023-05-10 使用mazdutide的治疗方法

Publications (1)

Publication Number Publication Date
AU2023281591A1 true AU2023281591A1 (en) 2025-01-02

Family

ID=89026916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023281591A Pending AU2023281591A1 (en) 2022-06-01 2023-05-10 Treatment method using mazdutide

Country Status (8)

Country Link
US (1) US20250296973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4534095A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025518227A (cg-RX-API-DMAC7.html)
KR (1) KR20250021331A (cg-RX-API-DMAC7.html)
CN (1) CN119584980A (cg-RX-API-DMAC7.html)
AU (1) AU2023281591A1 (cg-RX-API-DMAC7.html)
CA (1) CA3257926A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023231730A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202617173A (zh) * 2021-06-25 2026-05-01 大陸商信達生物製藥(蘇州)有限公司 Mazdutide的應用
EP4788362A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
WO2026002224A1 (en) * 2024-06-27 2026-01-02 Innovent Biologics (Suzhou) Co., Ltd. Method of treating polycystic ovary syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
CN111423506B (zh) * 2019-11-08 2023-06-27 成都奥达生物科技有限公司 一种glp-1化合物
TW202617173A (zh) * 2021-06-25 2026-05-01 大陸商信達生物製藥(蘇州)有限公司 Mazdutide的應用

Also Published As

Publication number Publication date
US20250296973A1 (en) 2025-09-25
KR20250021331A (ko) 2025-02-12
CA3257926A1 (en) 2025-04-09
EP4534095A2 (en) 2025-04-09
EP4534095A4 (en) 2026-05-27
CN119584980A (zh) 2025-03-07
WO2023231730A3 (zh) 2024-01-25
WO2023231730A2 (zh) 2023-12-07
JP2025518227A (ja) 2025-06-12

Similar Documents

Publication Publication Date Title
US20250296973A1 (en) Treatment method using mazdutide
EP4360641A1 (en) Use of mazdutide
JPH01233227A (ja) 高インシュリン症の二次効果治療及び予防用医薬組成物
JP2024038042A (ja) 肥満の治療および体重管理のためのglp-1組成物
WO2024042518A1 (en) Glp-1 receptor antagonist and methods of use thereof
US5700776A (en) Medicaments comprising glicentin as active ingredient
HK40118093A (en) Treatment method using mazdutide
CN110038114B (zh) 一种多肽在制备预防或治疗代谢综合征药物中的用途
HU193522B (en) Process for producing pharmaceutical preparations containing human proinsulin
HK40110048A (en) Use of mazdutide
JP2023518645A (ja) Glp-1の投薬レジメン
KR20250095833A (ko) 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
WO2025073289A1 (en) Methods of treating diabetes and obesity
WO2026037397A1 (zh) Glp-1类似物的医药用途
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
TW202140061A (zh) 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑
HK40094446A (en) Glp-1 dosing regimen
TW202529797A (zh) Glp-1類似物治療代謝疾病的方法及醫藥用途
KR20260022330A (ko) 대사 장애의 치료에 사용하기 위한 glp-1 유사체
TW202506170A (zh) 糖尿病之治療
HK40083623A (en) Dosing regimen of glp-1
RU2022104898A (ru) Слитый белок fgf21 fc, слитый белок glp-1 fc и комбинированный терапевтический агент, включающий их, и их применение
HK40039237A (en) Glp-1 analogue beinaglutide composition for treating obesity and weight management